| Biomarker ID | 490 |
| PMID | 20850153 |
| Year | 2010 |
| Biomarker | Age+ Family History+ PCA3 + %fPSA+ Prostate Volume+ sPSA |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Urine |
| Subjects | Humans |
| Regulation | Upregulated in Positive Biopsy |
| Odds Ratio/Hazard Ratio/Relative Risk | Multivariate: 1.0152 (95% CI: 1.01-1.02) |
| Effect on Pathways | NA |
| Experiment | Positive PCa Biopsy Vs Negative PCa Biopsy |
| Type of Biomarker | Diagnostic |
| Cohort | A subset of 1,140 subjects from the REDUCE study cohort provided urine samples for PCA3 analysis before year 2 and/or year 4 biopsy. Of the 1,140 specimens 1,072 provided sufficient mRNA for PCA3 analysis |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.753 (95% CI: 0.712-0.793) |
| Accuracy | NA |
| Level Of Significance | p <0.0001 |
| Method Used | NA |
| Clinical | No |
| Remarks | Patients were taken from placebo arm of REDUCE trial with identifier: NCT00056407. PSA Treated as a continous variable |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | PCA3 |